GBC AG cuts MustGrow Biologics price target to CAD 2.51, keeps Buy
GBC AG lowered its target from CAD 2.70 and reiterated a Buy rating on MustGrow Biologics. It also cut FY2026 revenue forecast to CAD 3.5 million from CAD 4.5 million.
GBC AG lowered its target from CAD 2.70 and reiterated a Buy rating on MustGrow Biologics. It also cut FY2026 revenue forecast to CAD 3.5 million from CAD 4.5 million.